Patent · US Active

FGF-9 variants and methods of use thereof

US8916522B2 · kind B2 · utility

4Cited by

32References

5Claims

0Family size

Assignee

PROCHON BIOTECH LTD. · IL

Inventors

Oren Bogin · Mazkeret Batya, IL
Avner Yayon · Afula, IL

Key dates

Filing date	Jul 30, 2013
Grant date	Dec 23, 2014
Priority date	—
Expiry date	Jul 30, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/1346
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.